The lawsuit further alleges that the makers of Ozempic and Mounjaro acknowledge that gastrointestinal events are well-known side effects of GLP-1 class drugs
doi:10.1093/ajcn/75.2.295
Musleh also notes that, while you can get hypoglycemic (low blood sugar) when using Ozempic, research shows its more common when using the drug with another diabetes or insulin medication
In a 2021 trial in nondiabetics with obesity, semaglutide 2.4mg/weekly induced a 35% reduction in the subjects ad libitum (unrestricted) energy intake after just 20 weeks
The required labeling for some GLP-1 receptor agonists indicated for glycemic control in patients with type 2 diabetes include warnings and precautions regarding acute gallbladder disease in the U.S
B., Vancampfort, D., Richards, J., et al